Protein S100A8/A9: A Potential New Biomarker for Pancreatic Diseases

Standard

Protein S100A8/A9: A Potential New Biomarker for Pancreatic Diseases. / El Gammal, Alexander Tarek; Sturm, Jörn H.; Pinnschmidt, Hans; Hofmann, Bianca Thidahan; Bellon, Eugen; Ghadban, Tarik; Melling, Nathaniel Timon; Bachmann, Kai Alexander; Izbicki, Jakob; Bockhorn, Maximilian; Güngör, Cenap; Perez, Daniel.

in: Int J Clin Endocrinol Metab, Jahrgang 3, Nr. 1, 2017, S. 023-028.

Publikationen: SCORING: Beitrag in Fachzeitschrift/ZeitungSCORING: ZeitschriftenaufsätzeForschungBegutachtung

Harvard

APA

Vancouver

Bibtex

@article{4302344ca0744f2bb167ea87dc03b456,
title = "Protein S100A8/A9: A Potential New Biomarker for Pancreatic Diseases",
abstract = "Objectives: S100A8/A9 expression has been linked to carcinogenesis and inflammation. We hypothesized that S100A8/A9 protein serum levels are a useful stratification marker for patients with pancreatic ductal adenocarcinoma (PDAC), intraductal papillary mucinous neoplasm (IPMN) or chronic pancreatitis (CP).Methods: S100A8/A9 serum levels were analysed in PDAC, CP and IPMN patients and compared to S100A8/A9 healthy donor controls (HD) using ELISA. S100A8/A9 levels and clinical data were statistically analysed.Results: Out of 134 patients included, 84 were diagnosed with PDAC (46%), 30 patients with IPMN (16%) and 20 patients with CP (11%), 50 patients were HD (27%). When compared to HD (343.3 ng/ml), S100A8/A9 serum concentration was elevated in PDAC (402.0 ng/ml, p = 0.001) and CP patients (426.51 ng/ml p < 0.001). Also, S100A8/A9 levels were elevated in PDAC compared to IPMN group (369.0 ng/ml p = 0.026) and in CP compared to IPMN group (p = 0.001). A multivariate model including age, gender, leukocyte levels, C-reactive protein (CrP), S100A8/A9 and CA 19-9 concentrations reported a diagnostic sensitivity of 74.8%.Conclusion: S100A8/A9 serum levels are increased in patients with PDAC, CP, and IPMN and might be useful to distinguish malignant and inflammatory diseases from normal and non-malignant pathological conditions.",
author = "{El Gammal}, {Alexander Tarek} and Sturm, {J{\"o}rn H.} and Hans Pinnschmidt and Hofmann, {Bianca Thidahan} and Eugen Bellon and Tarik Ghadban and Melling, {Nathaniel Timon} and Bachmann, {Kai Alexander} and Jakob Izbicki and Maximilian Bockhorn and Cenap G{\"u}ng{\"o}r and Daniel Perez",
year = "2017",
language = "English",
volume = "3",
pages = "023--028",
journal = "Int J Clin Endocrinol Metab",
issn = "1726-9148",
publisher = "Kowsar Publishing Company",
number = "1",

}

RIS

TY - JOUR

T1 - Protein S100A8/A9: A Potential New Biomarker for Pancreatic Diseases

AU - El Gammal, Alexander Tarek

AU - Sturm, Jörn H.

AU - Pinnschmidt, Hans

AU - Hofmann, Bianca Thidahan

AU - Bellon, Eugen

AU - Ghadban, Tarik

AU - Melling, Nathaniel Timon

AU - Bachmann, Kai Alexander

AU - Izbicki, Jakob

AU - Bockhorn, Maximilian

AU - Güngör, Cenap

AU - Perez, Daniel

PY - 2017

Y1 - 2017

N2 - Objectives: S100A8/A9 expression has been linked to carcinogenesis and inflammation. We hypothesized that S100A8/A9 protein serum levels are a useful stratification marker for patients with pancreatic ductal adenocarcinoma (PDAC), intraductal papillary mucinous neoplasm (IPMN) or chronic pancreatitis (CP).Methods: S100A8/A9 serum levels were analysed in PDAC, CP and IPMN patients and compared to S100A8/A9 healthy donor controls (HD) using ELISA. S100A8/A9 levels and clinical data were statistically analysed.Results: Out of 134 patients included, 84 were diagnosed with PDAC (46%), 30 patients with IPMN (16%) and 20 patients with CP (11%), 50 patients were HD (27%). When compared to HD (343.3 ng/ml), S100A8/A9 serum concentration was elevated in PDAC (402.0 ng/ml, p = 0.001) and CP patients (426.51 ng/ml p < 0.001). Also, S100A8/A9 levels were elevated in PDAC compared to IPMN group (369.0 ng/ml p = 0.026) and in CP compared to IPMN group (p = 0.001). A multivariate model including age, gender, leukocyte levels, C-reactive protein (CrP), S100A8/A9 and CA 19-9 concentrations reported a diagnostic sensitivity of 74.8%.Conclusion: S100A8/A9 serum levels are increased in patients with PDAC, CP, and IPMN and might be useful to distinguish malignant and inflammatory diseases from normal and non-malignant pathological conditions.

AB - Objectives: S100A8/A9 expression has been linked to carcinogenesis and inflammation. We hypothesized that S100A8/A9 protein serum levels are a useful stratification marker for patients with pancreatic ductal adenocarcinoma (PDAC), intraductal papillary mucinous neoplasm (IPMN) or chronic pancreatitis (CP).Methods: S100A8/A9 serum levels were analysed in PDAC, CP and IPMN patients and compared to S100A8/A9 healthy donor controls (HD) using ELISA. S100A8/A9 levels and clinical data were statistically analysed.Results: Out of 134 patients included, 84 were diagnosed with PDAC (46%), 30 patients with IPMN (16%) and 20 patients with CP (11%), 50 patients were HD (27%). When compared to HD (343.3 ng/ml), S100A8/A9 serum concentration was elevated in PDAC (402.0 ng/ml, p = 0.001) and CP patients (426.51 ng/ml p < 0.001). Also, S100A8/A9 levels were elevated in PDAC compared to IPMN group (369.0 ng/ml p = 0.026) and in CP compared to IPMN group (p = 0.001). A multivariate model including age, gender, leukocyte levels, C-reactive protein (CrP), S100A8/A9 and CA 19-9 concentrations reported a diagnostic sensitivity of 74.8%.Conclusion: S100A8/A9 serum levels are increased in patients with PDAC, CP, and IPMN and might be useful to distinguish malignant and inflammatory diseases from normal and non-malignant pathological conditions.

M3 - SCORING: Journal articles

VL - 3

SP - 23

EP - 28

JO - Int J Clin Endocrinol Metab

JF - Int J Clin Endocrinol Metab

SN - 1726-9148

IS - 1

ER -